Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Montis Biosciences, a Belgium-based solid tumour cancer therapy spinout of KU Leuven and VIB, has launched with €8.4m ($9.1m) in seed funding from investors including Pfizer Ventures, the corporate venturing arm of pharmaceutical firm Pfizer. The round also included Polaris Partners, Alsa Ventures and Droia Ventures, with the latter also credited as a co-founder. Montis hopes to commercialise cancer treatments that exploit solid tumour interactions with perivascular macrophages, white blood cells responsible for directing immune cells into blood vessels. The…
